Oncology

 

Read more about our commitment in Oncology

 

Targeting Direct Hits to Cancer Cells

Learn more »

Striving for the Right Tools to Fight Brain Tumors with Kyle Holen

Learn more »

‘Patients Need To Move On With Their Lives’: Q&A With Lori Styles, M.D., Pharmacyclics

Learn more »

 

 

View all of our Oncology press releases:

A Christmas Toast and a Call That Changed Everything

A friendly rivalry fueled James and Trudy’s relationship for 45 years. When James was diagnosed with chronic lymphocytic leukemia, that competitive spirit came in handy.

AbbVie Announces Pivotal Phase 2 Trial Evaluating VENCLYXTO™ (venetoclax) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion to be Presented at 22nd European Hematology Association (EHA) Annual Congress

- First oral presentation of full Phase 2 trial results with overall response rate (ORR), inclusive of complete and partial remission rates(1)

Important Facts About Acute Myeloid Leukemia

Leukemia is a cancer of the blood cells of which there are several types.

New Data Presented at ASCO 2017 Finds IMBRUVICA® (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients

NORTH CHICAGO, Ill., June 5, 2017 /PRNewswire/ -- IMBRUVICA (ibrutinib) reduced cells that may play an important role in the survival and proliferation of chronic lymphocytic leukemia (CLL), without negatively impacting non-cancerous immune system cells, through one year of treatment, according to new data presented today at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (poster session: 8:00 a.m. – 11:30 a.m. CDT; abstract #7524).1 The data regarding IMBRUVICA, a first-in-class Bruton's tyrosine kinase (BTK) inhibitor, were announced by AbbVie (NYSE: ABBV), a global biopharmaceutical company. IMBRUVICA is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc.

Long-Term IMBRUVICA® (ibrutinib) Efficacy and Safety Data at ASCO 2017 Show Sustained Survival Rates in Up to Four Years in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients, Including Those with High-Risk Disease

NORTH CHICAGO, Ill., June 5, 2017 /PRNewswire/ -- Long-term follow-up results from the pivotal Phase 3 RESONATE™ trial (PCYC-1112) showed continued survival rates in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) treated with IMBRUVICA (ibrutinib) up to four years, according to new data presented today at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (poster session: 8:00 a.m. – 11:30 a.m. CDT; poster discussion: 1:15 p.m. – 2:30 p.m. CDT). The data regarding IMBRUVICA, a first-in-class Bruton's tyrosine kinase (BTK) inhibitor and the first chemotherapy-free treatment for patients with CLL, were announced by AbbVie (NYSE: ABBV), a global biopharmaceutical company. IMBRUVICA is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc.